Canada: Plus Ça Change…? The New Amendments To The Food And Drug Regulations And The Patented Medicines (Notice Of Compliance) Regulations

Last Updated: May 16 2007
Article by Peter E. J. Wells

On October 5, 2006, amendments to section C.08.004.1 of the Food and Drug Regulations and to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regs) came into force. Among the objects of the amendments are "to provide new drugs with an internationally competitive, guaranteed minimum period of market exclusivity of eight years"1 and the restoration of "the balanced policy underlying the PM(NOC) Regs by reaffirming the rules for listing patents on the register and clarifying when listed patents must be addressed."2

For the benefit of the readers, it might be useful to state some basic principles of Canadian patent law to understand why there is a special regime for pharmaceutical patents. A patent results from a bargain between the inventor and the Government of Canada – in exchange for the inventor disclosing in her patent application everything a skilled worker in the relevant field would need to duplicate the invention, the Government of Canada grants the inventor a period of exclusivity for practicing that invention once the patent office is satisfied that the invention is entitled to patent protection. This period of exclusivity for patents issued from applications filed on or after October 1, 1989, is 20 years from the date of the application. If two inventors file an application for the same invention, the first person to file is the one entitled to the patent. This "first to file" system encourages inventors to initiate the application process as quickly as possible.

Once the inventor of a new machine or new process; for example of making shoes, has made his application, he is free to begin marketing the invention3. However, the inventor of a new drug or a new process for making or administering a drug is not so lucky since the Food and Drugs Act prohibits anyone from marketing a medicine until she has obtained approval to do so by receiving a Notice of Compliance (NOC) from Health Canada (HC). When a new drug is submitted for approval to HC, the applicant must supply clinical data sufficient to demonstrate safety and efficacy of the new drug. HC will issue the applicant an NOC only if they are satisfied that the submitted clinical data supports the claims.

For the applicant, gathering the required clinical data is an expensive and time-consuming process that may take several years. While the inventor of the new drug is gathering this data, the period of patent exclusivity is effectively wasted, since the drug cannot be marketed until the manufacturer has received the NOC. By the time the NOC is issued, the patent may only have 8 to 10 years of life left. The effect of the drug approval process is to shorten the actual period of market exclusivity that the inventor of a new drug receives compared to the period of market exclusivity that the inventor of a device that does not require regulatory approval will have.

Food and Drug Regulations Amendments

Food and Drug Regulations Amendments Section C.08.004.1 of the Food and Drug Regulations is the "so-called" data protection provision. A subsequent applicant for approval to market a drug for which an NOC has already been issued is not required to duplicate clinical trials conducted by the first NOC holder, but is permitted to demonstrate safety and efficacy by submitting bioequivalence data against the formulation for which the NOC was originally issued. In effect, the subsequent applicant derives a benefit from the first applicant's clinical data. Under the amendments to the Food and Drug Regulations, the first party to obtain an NOC for a drug will have an eight-year period of exclusivity starting from the date it received its NOC based on the clinical data. A subsequent applicant for marketing approval who seeks to establish safety and efficacy by comparing its product to the product that received the first NOC will not be able to file an application until six years after the first NOC was issued. HC will not be permitted to issue an NOC to that applicant until eight years after the issuance of the first NOC. The additional two-year period will correspond in most cases to the 24-month automatic stay under the PM(NOC) Regs. If the first applicant submits additional studies with the goal of increasing knowledge about the behaviour of the drug in pediatric populations which will assist health professionals and others in making informed choices about drug therapy, it will be entitled to an additional six months data protection.

The amended regulation also contains a definition of "innovative drug" which excludes variations of previously approved drugs such as salts, esters, enantiomers, solvates or polymorphs from obtaining data protection. A registry of innovative drugs will be established and maintained, listing the name of the drug, the active ingredient, and the date data protection expires, including any pediatric extension.

Another important point to note is that a drug is only entitled to data protection so long as it is being marketed in Canada. If a drug is withdrawn after approval, the drug will lose its data protection.

The amended regulation applies in respect to all drugs for which an NOC was issued on or after June 17, 2006.

PM (NOC) Regs Amendments Since first being enacted in 1993, the PM(NOC) Regs have resulted in an impressive body of case law. Whether the stated desire of reducing the volume of litigation under these regulations will be realized remains to be seen. Nevertheless, a number of issues have been addressed in the amendments.

Under the previous version of the PM(NOC) Regs, the party filing the first New Drug Submission (NDS) was permitted to submit a list of patents that included claims to the medicine itself and to the use of the medicine. That party was also able, at any later date, to file an amended list within 30 days of issuance of any patent issued after the granting of the NOC to add the new patent, provided that its application had been filed before the submission in support of the NOC.

Perhaps one of the strategies under the old PM(NOC) Regs that vexed most generics companies was the rolling series of additions to the patent list. A generic manufacturer would file its submission, usually in the form of an abbreviated new drug submission (ANDS), and serve its notice of allegations (NOA) explaining either that it was content to wait until all the patents on the patent list had expired to receive its NOC, or explaining why the patents were either invalid or would not be infringed. One amendment to the PM(NOC) Regs now makes filing of the submission by the generic manufacturer a precondition of serving an NOA. The innovator would have 45 days after being served with the NOA to commence an application in court to prohibit HC from issuing an NOC until all the patents on the list had expired. This would trigger an automatic 24-month period during which HC would not be permitted to issue an NOC so that the Court could determine the respective rights of the two drug makers. Under the old regulations an innovator could add a new patent to the list by filing a supplementary new drug submission (SNDS) for certain changes in order to obtain an updated NOC. Adding a new use, such as "social phobia (social anxiety disorder)" for a drug previously approved as an "antidepressant / antiobsessional / antipanic agent"4 could be used to justify the filing of a SNDS so that a new patent could be added to the list when the new NOC was issued. The generic would then have to amend its application to deal with the new patent, which would trigger a further 24-month delay. Even if the newly added patent concerned a different formulation or a different use than the one for which the generic sought approval and the generic ultimately justified its allegation of non-infringement, it would still have been delayed for another two years.

The amendments contain a number of changes to prevent this practice from continuing. Firstly, the patents on the list must be relevant to the drug product that the applicant is approved to sell under its NOC. Secondly, the patent list is tied to the particular NDS or SNDS and may only include patents for which an application had been made prior to the filing of that NDS or SNDS. Thus, while an innovator may submit a SNDS to obtain approval for a change in use or for a change in formulation or dosage form, its patent list will be tied to that specific formulation. Any new patents that claim that use, formulation or dosage form may be added. However, a patent for a new physical form of the active pharmaceutical ingredient (API) will not qualify for inclusion on such a list. Thirdly, once a generic company files its ANDS the patent list is "frozen" as of that date, and it does not need to address any new patent added to the patent list for that drug after the date of its ANDS.5

The transitional provisions, however, may cause some difficulty. According to the Regulatory Impact Analysis Statement, although freezing the register and eliminating early NOAs is thought to be the most expedient solution to the problem of multiple stays under the PM(NOC) Regs, considerable confusion could result from the immediate application of these changes to pre-existing facts. The transitional rules accompanying the amendments thus provide that, for those generic manufacturers who have already filed a submission or supplement for an NOC in respect of a generic version of an innovative drug with patents on the register, the filing date for the purposes of amended section 5 is deemed to be the date the amendments come into force."6 The transitional provision for subsections 5(1) and 5(2) provide that "the date of filing of the submission is deemed to be the date of the coming into force of these Regulations."7

The problem is that the PM(NOC) Regs require that certain steps are either concurrent with or follow the filing of the submission. For instance, if the generic manufacturer has already served its NOA, it will pre-date the deemed filing date for its submission, contrary to subsection 5(3) of the amended regulations. If that problem is solved by assuming that the NOA is deemed to have been served on the date the regulations came into force, does this give an innovator that had not commenced an application to court a further 45 days from October 5, 2006 to reconsider its decision? It would appear that the intended effect would have been achieved had the transitional provision stated: "the date of filing of the submission is deemed, for the purposes of subsection 5(4) only, to be the date of the coming into force of these Regulations."

The amendments also contain a provision intended to parallel the data protection provision that denies protection to drugs that have been withdrawn from the market. If a drug is no longer being marketed, the Minister is required to delete any listed patents. This provision is subject to a 90-day grace period so that technical withdrawals such as one due to a change in manufacturer will not result in deletion of listed patents before the approval can be moved over to the new manufacturer.

The 24-month automatic stay is a powerful instrument and to discourage its frivolous use, the PM(NOC) Regs contained a provision permitting the generic company to seek compensation for the period of time it was kept from the market in the event the court held that the allegations in the NOA had been justified. Under the old form of the regulation the generic manufacturer could choose between proving its actual loss (damages) or seek to have the innovator pay the profits that was earned during that 24-month period. The amended regulation now restricts the generic manufacturer to proving its actual loss and also specifies that the Minister is not liable for any such damages.


The amendments to the Food and Drug Regulations and the PM(NOC) Regs represent an effort by the Government of Canada to address a number of problems that had been encountered in practice and to restore the balance between innovator and generic manufacturers of pharmaceutical products to the point which the Government believes protects their interests and also serves the interests of the Canadian public. While the provisions appear to effectively address a number of practical problems that were discovered with the prior version of the regulations, the transitional provisions with respect to subsections 5(1) and 5(2) may well require either legislative or judicial clarification to avoid a number of unintended consequences.


1 Regulatory Impact Analysis Statement for the amendments to the Food and Drug Regulations

2 Regulatory Impact Analysis Statement for the PM(NOC) Regs amendments

3 In Canada an inventor has one year after taking a step which makes the invention available to the public within which to apply for a patent. However, many countries have "absolute novelty" rules which prevent inventors from obtaining patent protection if they published the invention before filing a patent application.

4 Apotex Inc. v. Minister of Health (1999), 87 C.P.R. (3d) 271 (F.C.T.D.) affirmed 11 C.P.R. (4th) 538 (F.C.A.)

5 Subsection 5(4) of the amended PM(NOC) Regs

6 Regulatory Impact Analysis Statement for the PM(NOC) Regs amendments

7 Section 7 of the amending regulation for the PM(NOC) Regs

Peter Wells is a partner in the Intellectual Property Group in Toronto.

This article originally appeared in The News of Course (The N.O.C) published by the Canadian Association of Professional Regulatory Affairs (CAPRA).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.